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Medical MMICs Can Save 
Even the Smallest of 
Human Lives 
by Jo Ann McDonald, US Correspondent 
GaAs MMICs have long been regarded as a "niche technology.'" When looking into the 
applications of those MMICs in actual, fielded systems, some of those "niches" are incredibly 
important. A case in point is what Microwave Medical Systems, Inc. (MMS) of Acton, 
Massachusetts, USA, is doing with MMIC technology. Because of the MMIC-based 
devices and systems MMS has developed for those who require critical care, even 
the smallest of humans - newborn babies - can now be saved. 
M MS is a small company in 
Massachuset ts  mak ing  
monolithic microwave inte- 
grated circuit (MMIC) based systems 
that help heal even our most fragile 
humans...newborn babies. MMS is a 
development stage company that 
conceives, designs, and develops 
medical devices that use microwaves 
to generate heat, measure and moni- 
tor temperature, and measure mo- 
tion. By combining these capabilities 
with their proprietary software, MMS 
develops products that fall into two 
primary categories: blood and intra- 
venous (IV) fluid delivery systems, 
and minimally invasive devices for 
localized heating of subcutaneous 
tissue. 
Readers of Ill- Vs Rev iew may recall 
that Kenneth Carr, founder of MMS, 
provided attendees of the 1995 GaAs 
IC Symposium an overview of the 
need for products uch as the small, 
lightweight, IV Injection Site Monitor 
which MMS has developed, based on 
passive microwave radiometry, that 
can address the requirements of the 
pediatric patient population. In May 
of 1996, with the help of their 
development partner, Arrow Interna- 
tional, Inc., MMS' patented micro- 
wave ablat ion techno logy  was 
approved by the Federal  Drug 
Agency (FDA) for human trials. The 
approval covers a system approxi- 
mately the size of a quarter coin, and 
suitable primarily for full sized hu- 
mans. The next step is to get similar 
approval for an even smaller unit, for 
the tiniest of newborns, neonatals. 
Roots at M/A-COM 
Concerns for how we might better 
treat our seriously ill people has 
driven MMS' MMIC development 
from its inception in September of 
1985. Originally a part of M/A-COM, 
the company s roots are firmly 
planted in medical applications of 
extraordinary importance. In 1977, as 
part of an internally funded program 
to expand commercial applications 
of microwave technology,  M/A- 
COM's Technology Center, under 
the direction of Kenneth L. Carr, 
established a program to investigate 
the application of microwave tech- 
nology to the detection and treat- 
ment of cancer. In work supported 
by NASA/Langley Research Center, 
and working with the Department of 
Radiation Oncology and Biophysics at 
the Eastern Virginia Medical School, 
Carr produced a prototype dual 
mode microwave system which com- 
bined the use of passive microwave 
radiometry with an active microwave 
transmitter. The promising work led 
to further studies at Tufts New 
England Medical Center, Nippon 
Medical School and Johns Hopkins 
University Hospital. The result was a 
first product, the Microwave Disin- 
fection Device. A similar transfer of 
technology has resulted in develop- 
ment of prototypes for extravasation 
detection and blood/IV fluid warm- 
ing applications. 
The spinoff of Carr from M/A-COM 
into MMS began in 1985 when M/A- 
COM underwent a restructuring em- 
phasizing their military market. Carr, 
who was a M/A-COM Group VP at 
the time, spun the medical applica- 
tions out with the blessing of M/A- 
COM and the objective of develop- 
ing, manufacturing, and marketing 
the devices and systems for the 
medical community. In September 
of 1993, Arrow International entered 
into a strategic agreement with MMS 
to purchase approximately 17% of 
MMS' Common Stock for $3.0 million. 
In August of 1994, MMS moved from 
its facility in Littleton, MA, to a 15,000 
sq. ft. facility in nearby Acton, MA, 
which provided additional manufac- 
turing space. 
In addition to the fluid delivery 
systems and minimally invasive de- 
vices for heating of tissue, MMS is 
developing a variety of stand-alone 
microwave-based products which in- 
cludes a breast screening system for 
early detection of tumors, a radio- 
metric thermometer, and a laboratory 
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device for rapid tissue fixation. Ac- 
cording to Kenneth Carr, there are 
numerous potential applications for 
microwave technology in medicine 
which are in various stages of devel- 
opment by MMS. Patents have been 
issued or are pending on all of these 
and several, including the adult ver- 
sion of the 1V Injection-Site Monitor 
addressed in the 1995 IEEE GaAs IC 
Symposium paper  titled: "Use of 
Gallium Arsenide In Medical Applica- 
tions" have received FDA clearance 
for marketing. 
Medical research 
Another key product  for use in 
critical patient care, which was de- 
veloped in conjunction with the U.S. 
Army Medical Research and Materiel 
Command and gained FDA approval 
in 1993, is the ThermoStat  900 
system for in-line warming of physio- 
logic fluids. It represents the first 
time use of passive microwave radio- 
metry for noninvasive measurement 
and control of the temperature of 
liquids in motion. The device pro- 
vides in-line warming of blood and IV 
fluids to meet the needs of patients in 
operat ing and emergency  rooms. 
When changes to inlet temperature 
or flow rate occur, the device re- 
sponds quickly by adjusting the 
power  level. Unlike conventional 
dry warmers which are inadequate 
at high flow rates, the ThermoStat 
900 operates efficiently in these flow 
regimes. Prior to this product, rapid 
infusion required the use of a warm 
water bath, which increased the risk 
of contamination and resulted in 
increased pathlength and large prim- 
ing fluid volume. MMS has continued 
developing a family of products to 
address related market needs which 
include portable devices for use on- 
board emergency vehicles. Sales to 
date exceed $1.25 million. MMS 
earned the 1995 Massachusetts Small 
Business Innovation Award for devel- 
opment of the ThermoStat 900. 
According to Carr, "all of our 
products address areas of demon- 
strable need and the market for many 
of these products is of significant 
size. In the area of blood and fluid 
delivery, for example, MMS is devel- 
oping a device to provide rapid 
thawing of frozen blood, which could 
increase the nation's blood supply by 
significantly reducing waste." MMS' 
fluid delivery product line represents 
the broadest line of products for use 
in the fluid delivery path in the 
industry. "Our approach to inactivat- 
ing the HIV virus in blood could 
potential ly lead to a safer blood 
supply.  Accord ing to pub l i shed  
sources, in the area of minimally 
invasive devices, our myocardial abla- 
tion device addresses a patient popu- 
lation of approximately 200,000 with 
an estimated market size in excess of 
$100 million," says Carr. 
importance of monitoring infiltra- 
tion of fluid Technologists at the '95 
Symposium were stirred by the im- 
portance of the MMIC application. 
Indeed, "extravasation" is a serious 
threat to patients. Defined as the 
unwanted occurrence of infiltration 
of fluid during IV infusion beyond the 
vein or artery into the surrounding 
tissue, extravasation of IV fluids in 
children can have especially serious 
consequences when gross incidents 
occur which, unfortunately, is fre- 
quently. When cancer patients nor- 
maliy receive therapeutic drugs by 
IV, a hollow needle or catheter is 
normally inserted into a superficial 
artery or vein. Improper placement 
or patient movement can easily dis- 
lodge the needle or catheter which 
easily leads to an accumulation of 
liquid in the perivascular, or sur- 
rounding, tissue. The results run from 
serious discomfort o tissue destruc- 
tion. The startling figures tell the tale. 
The incidence of infiltration and 
extravasation i IV lines in place for 
12-24 hours or longer is between 15- 
78%. Because of their tiny size, the 
incidence in neonates and infants 
ranges between 58-78%. Although it 
may be benign, the morbidity spec- 
trum ranges from pain, swelling and 
phlebitis to skin sloughing and tissue 
necrosis which often prolongs hospi- 
talization and can even lead to the 
necessity for skin grafts and even 
amputations. Nurses tend to spend 1- 
2 hours per day simply attending to 
the IVs. The smaller the child, the 
more often discovery is delayed since 
diagnosis is difficult with an unaided 
eye. Plus, little ones are unable to 
communicate  their pain and are 
more prone to tissue necrosis be- 
cause of the limited space on which" 
to attach the usually cumbersome 
equipment. 
Early attempts by MMS to provide 
infiltration detection included mea- 
suring the swelling and the surface 
temperature changes, using thermis- 
tor sensing. Although both techni- 
ques could terminate flow in the 
event of problems, neither could do 
the necessary early detect ion of 
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buildup of toxic fluids. Response 
time was simply too slow and subject 
to false alarms because of having to 
be in contact with the skin's surface. 
Another technique, inline pressure 
based sensing, had the drawback of 
requiring visual monitoring of the IV 
site pressure readings displayed on 
the pump. 
The passive microwave radiometric 
technique has proved to be the best 
route to go. "It is noninvasive to the 
fluid path, independent of the nee- 
dle/catheter diameter, and indepen- 
dent of age and the condition of the 
patient, particularly with respect to 
blood vessels," says Carr. MMS's 
microwave technique has been pro- 
fessionally compared and evaluated 
with techniques involving pressure 
measurement and has proved to be 
far more sensitive, faster, and more 
effective in providing early detection 
of extravasation. 
Adaptation to 
paediatric market 
MMS is now readying the smaller, 
aspirin sized system for FDA approval 
and market use. In order to adapt the 
radiometric technology for the pae- 
diatric market, it was essential that 
the transducer be very small and 
l ightweight to accommodate  the 
small size of the area where the IV 
infusions are administered. An exam- 
ple would be the infant's or neonate's 
tiny foot. To achieve such a small 
antenna size necessitates the use of 
higher microwave frequencies ince 
the tissue of a tiny infant is consider- 
ably more absorptive at the higher 
frequency. 
MMS is now scouting for a worthy 
manufacturing partner for its aspirin 
sized, lightweight integrated milli- 
metre front end and antenna for their 
newest, and perhaps most important, 
pediatric product. '~¢ithout afford- 
able, high performance MMIC cir- 
cuits, the development of medical 
devices uch as this would simply not 
be possible," says Carr, citing that it 
has only been recently that cost- 
effective MMIC fabrication techni- 
ques have been in place to accom- 
plish the task. 
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